scispace - formally typeset
R

Robert F. Reynolds

Researcher at Pfizer

Publications -  82
Citations -  4498

Robert F. Reynolds is an academic researcher from Pfizer. The author has contributed to research in topics: Population & Ziprasidone. The author has an hindex of 30, co-authored 81 publications receiving 4135 citations. Previous affiliations of Robert F. Reynolds include Tulane University.

Papers
More filters
Journal ArticleDOI

Prevalence of the metabolic syndrome and overweight among adults in China

TL;DR: It is indicated that a large proportion of Chinese adults have the metabolic syndrome and that overweight has become an important public health problem in China, and there is an urgent need to develop national strategies for the prevention, detection, and treatment of overweight and the metabolic Syndrome.
Journal ArticleDOI

Prevalence, awareness, treatment, and control of hypertension in china.

TL;DR: The results indicate that hypertension is highly prevalent in China and the percentages of those with hypertension who are aware, treated, and controlled are unacceptably low, underscore the urgent need to develop national strategies to improve prevention, detection, and treatment of hypertension in China.
Journal ArticleDOI

Cardiac arrest and ventricular arrhythmia in patients taking antipsychotic drugs: cohort study using administrative data

TL;DR: The increased risk of cardiac arrest and ventricular arrhythmia in patients with treated schizophrenia could be due to the disease or its treatment, and the risk with thioridazine was no worse than that with haloperidol.
Journal ArticleDOI

Prevalence of cardiovascular disease risk factor clustering among the adult population of China: results from the International Collaborative Study of Cardiovascular Disease in Asia (InterAsia).

TL;DR: Prevention, detection, and treatment of CVD risk factor clustering should be an important component of a national strategy to reduce the increasing burden ofCVD in China.
Journal ArticleDOI

Serious cardiovascular events and mortality among patients with schizophrenia.

TL;DR: Among patients with schizophrenia, cardiovascular risk was inversely associated with intensity of use of antipsychotic drugs, suggesting that the observed risks may not be due to a simple or direct effect of drugs.